+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 20Years +
FEMALE
ID07651124

Safety Evaluation of Patient-Derived Tumor-Infiltrating Lymphocytes for Recurrent Ovarian Cancer Treatment

Led by Yong Wha Moon · Updated on 2026-06-16

6

Participants Needed

1

Research Sites

25 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to assess the safety and effectiveness of autologous tumor-infiltrating lymphocytes TILs in treating recurrent ovarian cancer. The study focuses on evaluating both the potential benefits and risks of this treatment approach, involving participants who have a cancerous lesion suitable for biopsy or surgery. The trial is designed to provide important safety data and preliminary efficacy insights. Participants will have tumor tissue collected through biopsy or surgery to culture enhanced tumor-infiltrating lymphocytes. These cultured cells, called CHA-TIL, will then be administered as a single intravenous infusion. The study includes a treatment period lasting 2 months, followed by a 4-month follow-up to monitor safety and response to therapy. Throughout the trial, participants will be closely monitored with evaluations of the cells ability to attack cancer cells and assessments of treatment-related toxicity, including lymphodepletion, CHA-TIL infusion, and high-dose IL2 therapy. The total observation time covers 6 months from treatment start, during which various safety and efficacy measures will be collected to understand the treatments impact.

CONDITIONS

Brief Title

To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer

Research Team

Y

Yong Wha Moon

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here